Clinical Trial Update: DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular Carcinoma [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating a DNAJB1-PRKACA fusion kinase peptide vaccine in combination with nivolumab and ipilimumab for fibrolamellar hepatocellular carcinoma; …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fibrolamellar Hepatocellular Carcinoma

Drugs mentioned

• DNAJB1-PRKACA Fusion Kinase Peptide Vaccine
• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Fibrolamellar Hepatocellular Carcinoma (FLC) | Phase 1 | Status: RECRUITING